Citi Maintains Buy Rating on AstraZeneca
Citi analyst Graham Parry has reaffirmed a buy rating for AstraZeneca, reflecting continued confidence in the company's outlook.
Stocks · News reference
Summit Therapeutics Announces Closing Of AstraZeneca's $2B Convertible Preferred Investment, Equivalent To $18.36/Share Of Common Stock
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Launches 'Meet Your Mark' Campaign to Promote Cancer Biomarker Testing
AstraZeneca has introduced a new public health campaign featuring actor Mark-Paul Gosselaar to encourage patients to discuss biomarker testing as a standard part of cancer care.
AstraZeneca Canada and Breast Cancer Canada Announce Research Funding
AstraZeneca Canada and Breast Cancer Canada are investing $200,000 in matched research funding to support initiatives addressing breast cancer survivorship.
AstraZeneca Enters Research Collaboration with Tremont AI
AstraZeneca has partnered with Tremont AI to develop and evaluate artificial intelligence models for preclinical safety assessment.
Summit Expands Ashburn Data Center Capacity by 60% as Hyperscale Demand Squeezes Enterprise Colocation Market
Summit announced a 60% capacity expansion at its Ashburn data center to address the shortage of colocation space for enterprises. The expansion comes as hyperscalers dominate the data center market, accounting for 59% of North American tenant demand, leaving traditional IT workloads struggling to secure capacity. The company's 'Colo in Any Market' program helps businesses find colocation options globally within 48 hours.
Citi Maintains Buy Rating and $43 Price Target for Summit Therapeutics
Citi analyst Yigal Nochomovitz has reaffirmed a Buy rating and a $43 price target for Summit Therapeutics Inc. (SMMT).